Cornerstone Capital Inc. cut its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 39.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,787 shares of the biotechnology company’s stock after selling 3,069 shares during the period. Cornerstone Capital Inc.’s holdings in Ligand Pharmaceuticals were worth $1,495,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in LGND. Janus Henderson Group PLC grew its stake in shares of Ligand Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 1,009,891 shares of the biotechnology company’s stock valued at $201,623,000 after buying an additional 14,491 shares in the last quarter. Ranger Investment Management L.P. acquired a new position in Ligand Pharmaceuticals in the second quarter worth approximately $81,424,000. Rice Hall James & Associates LLC increased its holdings in Ligand Pharmaceuticals by 1.4% in the first quarter. Rice Hall James & Associates LLC now owns 283,567 shares of the biotechnology company’s stock worth $56,614,000 after buying an additional 3,940 shares during the last quarter. Russell Investments Group Ltd. raised its position in Ligand Pharmaceuticals by 41.4% during the third quarter. Russell Investments Group Ltd. now owns 170,089 shares of the biotechnology company’s stock valued at $53,131,000 after acquiring an additional 49,785 shares in the last quarter. Finally, Bessemer Group Inc. raised its position in Ligand Pharmaceuticals by 2.2% during the third quarter. Bessemer Group Inc. now owns 144,545 shares of the biotechnology company’s stock valued at $45,151,000 after acquiring an additional 3,096 shares in the last quarter. 91.28% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, Director John W. Kozarich sold 500 shares of the firm’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $325.00, for a total value of $162,500.00. Following the sale, the director directly owned 42,122 shares of the company’s stock, valued at approximately $13,689,650. This trade represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jason Aryeh sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $320.05, for a total value of $960,150.00. Following the completion of the sale, the director directly owned 105,476 shares in the company, valued at approximately $33,757,593.80. This represents a 2.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 24,093 shares of company stock worth $7,384,287 in the last 90 days. Insiders own 5.60% of the company’s stock.
Analyst Ratings Changes
A number of analysts have issued reports on the stock. Leerink Partners initiated coverage on shares of Ligand Pharmaceuticals in a research note on Friday, August 14th. They issued an “outperform” rating and a $330.00 target price for the company. Oppenheimer restated an “outperform” rating and set a $326.00 price target (up from $285.00) on shares of Ligand Pharmaceuticals in a research note on Monday, August 3rd. HC Wainwright restated a “buy” rating and set a $358.00 price target on shares of Ligand Pharmaceuticals in a research note on Thursday, September 24th. Royal Bank Of Canada raised their price target on shares of Ligand Pharmaceuticals from $345.00 to $357.00 and gave the company an “outperform” rating in a report on Friday, October 30th. Finally, Barclays lifted their price objective on shares of Ligand Pharmaceuticals from $345.00 to $350.00 and gave the company an “overweight” rating in a research note on Wednesday, November 11th. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Ligand Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $355.38.
Check Out Our Latest Stock Report on LGND
Ligand Pharmaceuticals Trading Down 2.3%
NASDAQ:LGND opened at $301.71 on Tuesday. The company’s 50 day moving average is $302.03 and its 200-day moving average is $258.58. The company has a quick ratio of 1.19, a current ratio of 1.22 and a debt-to-equity ratio of 0.71. Ligand Pharmaceuticals Incorporated has a 12 month low of $175.89 and a 12 month high of $326.63. The firm has a market cap of $6.03 billion, a price-to-earnings ratio of 134.69, a P/E/G ratio of 5.52 and a beta of 1.16.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.34. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The business had revenue of $78.75 million during the quarter, compared to the consensus estimate of $77.00 million. During the same period in the prior year, the firm earned $3.09 EPS. Ligand Pharmaceuticals’s quarterly revenue was down 31.8% compared to the same quarter last year. Equities analysts anticipate that Ligand Pharmaceuticals Incorporated will post 2.35 EPS for the current year.
Ligand Pharmaceuticals Profile
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Further Reading
- Five stocks we like better than Ligand Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
